|
 Alzheimer's Research
 Merz - our research for your health. Merz is a leader in the field of Alzheimer research and developed the first drug for the treatment of moderate to severe Alzheimer s.
Alzheimer's Research: learn more about the different forms of diseases, current research, drugs, treatment, therapies and care. Alzheimer's Research is a topic that anyone of us should think about, because when growing old, everyone could be affected. Inform yourself about Alzheimer's Research now! The care for elderly people and their diseases are a topic for our society, whose importance grows each day. That's why we at Merz take Alzheimer's Research very serious, so that we can offer you the best drug for each treatment and therapy you need. Alzheimer's Research and Merz means research for your health. High-quality products and information about Alzheimer's Research can be found on our website. Visit us online and learn everything about Alzheimer's Research from one of Germany's leading health care companies. Our contribution to Alzheimer's Research: read here what we can do for you. Further links: Axura: Information for professionals.>>>
Inform yourself about Alzheimer's Research now.
Memantine , Alzheimer's Treatment . Glutamatergic overstimulation results in neuronal damage, a phenomenon that has been termed excitotoxicity. Calcium enters into the cell, and through secondary processes, the signal is recognized. Such excitotoxicity ultimately leads to neuronal calcium overload and has been implicated in neurodegenerative disorders. Senile Dementia , Dementia Care . The 2 large studies have shown positive effects of memantine in mild to moderate cases of vascular dementia. During physiological learning and memory processes, high concentrations of synaptic glutamate are transiently released. A signal is produced which due to the lower noise can be recognized and processed which leads to a symptomatic improvement in dementia symptoms. The starting point is the pathological release of glutamate, followed by elevated calcium concentrations. Alzheimer's Research , Alzheimer . Memantine has been developed as a monotherapeutic. At the same time, Memantine reduces caregiver time by more than 50 hours a month. A signal is produced which due to the lower noise can be recognized and processed which leads to a symptomatic improvement in dementia symptoms. Demenzkranke , Verwirrtheit Gedächtnisstörungen Short Term Memory Loss Symptoms Of Alzheimer's Disease . Calcium enters into the cell, and through secondary processes, the signal is recognized. Memantine produces symptomatic improvements in learning under conditions of tonic NMDA receptor activation in Alzheimer s disease. Alzheimer Erkrankung , Symptoms Of Alzheimer's Alzheimer's Disease Symptoms . The excitatory effect of chronically released glutamate effects the degeneration of cortical and subcortical neurons, thus leading to the occurrence of dementia symptoms. Merz Pharmaceuticals, as a member of Merz Pharma, is an innovative and international healthcare company, specializing in the research, development and marketing of pharmaceuticals for the treatment of neurological and psychiatric diseases. The excitatory neurotransmitter glutamate plays an important part in the development of neurodegenerative diseases like dementia. Memantine improves cognitive and psychomotor functioning, activities in daily living and the clinical global impression. Glutamate is the principal neurotransmitter in the brain. In studies of memantine, doctors assessed tolerability as good or very good in 93 percent of patients. Alzheimer's Drug Dementia Symptoms , Hirnleistungsstörungen . Memantine is a NMDA receptor antagonist and protects the glutamatergic system from pathological activation. Clinically-relevant doses of memantine produce improvements in learning under conditions of tonic NMDA receptor activation in Alzheimer's disease. Merz Pharmaceuticals, as a member of Merz Pharma, is an innovative and international healthcare company, specializing in the research, development and marketing of pharmaceuticals for the treatment of neurological and psychiatric diseases. Demenz Krankheit Alzheimer Behandlung NMDA-Schutz Demenz Früherkennung , Mild Cognitive Impairment Altersdemenz . Merz is a leader in the field of Alzheimer research and developed the first drug for the treatment of moderate to severe Alzheimer s. The excitatory effect of chronically released glutamate effects the degeneration of cortical and subcortical neurons, thus leading to the occurrence of dementia symptoms. Merz Pharmaceuticals, as a member of Merz Pharma, is an innovative and international healthcare company, specializing in the research, development and marketing of pharmaceuticals for the treatment of neurological and psychiatric diseases. The safety of the combination therapy was investigated in a postmarketing surveillance study. Alzheimer und Demenz , Glutamate Demenz Behandlung Demenz-Erkrankung . During learning and memory processes (i e transient high glutamate release), memantine - the fast, voltage-dependent NMDA-receptor antagonist - leaves the NMDA receptor for a short time. Memantine produces symptomatic improvements in learning under conditions of tonic NMDA receptor activation in Alzheimer s disease. Merz is a leader in the field of Alzheimer research and developed the first drug for the treatment of moderate to severe Alzheimer s. Memantine improves cognitive and psychomotor functioning, activities in daily living and the clinical global impression. Alzheimer's Disease Alzheimer Therapie , Symptoms Of Dementia . A significant improvement in cognitive performance is seen during treatment with the NMDA antagonist, especially when only small vessels are affected. Therefore memantine has a low potential for day-day interactions in these multimorbid patients. NMDA-Antagonist Forgetfulness , Glutamat Alzheimer Früherkennung . In the case of learning and memory processes, the transient synaptic release of glutamate causes more calcium to flow into the cell. vaskuläre Demenz , Lewy Body Dementia Demenz Therapie Vascular Dementia . Glutamate is the principal neurotransmitter in the brain. Gedächtnis , Demenz . Merz , Multi Infarct Dementia . Alzheimer's Dementia Axura , Vergesslichkeit Antidementiva Alzheimer's Caregiver . Stages Of Alzheimer's Disease , Akatinol Alzheimer's Support Hirnleistungsstörung NMDA-Protection . During physiological learning and memory processes, high concentrations of synaptic glutamate are transiently released. Due to its strong voltage-dependency, magnesium leaves the NMDA receptor. Alzheimer's , Demenzerkrankung Dementia . Memory Loss Pseudodemenz Alzheimer's Care , Dementia Treatment . Memantine is the first representative of a new class of Alzheimer drugs, a moderate affinity NMDA-receptor antagonist. Dementia And Alzheimer's Alzheimer Krankheit , Demenzkrank . Other franchise covered by Merz are hepatology, metabolic diseases and dermatology. Alzheimer's Symptoms , Mental Confusion . Memantine improves cognitive and psychomotor functioning, activities in daily living and the clinical global impression. Glutamate is the principal neurotransmitter in the brain. Dementia Medication Literatur , Erkennung Diagnose Studien . Glutamate stimulates a number of postsynaptic receptors, including the N-methyl-D-aspartate (NMDA) receptor, which has been particularly implicated in memory processes, dementia, and the pathogenesis of Alzheimer's disease. Memantine is well tolerated even in long-term therapy. Memantine is well tolerated even in long-term therapy. Medikamentkombinationen , Demenz Medikament . However, due to the already elevated calcium concentration, the signal can no longer be detected (occurrence of dementia symptoms). Therapy , Help . Diagnosis , Information Literature . Studies , Combination . Treatment Alzheimer's Therapie Demenz Alzheimer Medikament , Medication Alzheimer's .
 Alzheimer's Research
|
